Global Next-Generation Antibody Therapeutics Market

Global next-generation antibody therapeutics market to reach USD 14.26 million by 2030 from USD 4.69 million in 2019 at a CAGR of 13.69% by the forecast period.

Product Overview Use of a new improvised therapeutic antibody to form novel medicines for the treatment of different diseases includes next-generation antibody therapeutics. Next-generation antibody therapeutics have been clinically developed for many diseases by pharmaceutical and biotechnology firms. Next-generation antibody-based therapeutics for the treatment of different medical conditions such as cancer, infectious diseases, and autoimmune diseases improve the current properties of therapeutic antibodies. For the reason of their unique pharmacological characteristics, the science and development involved in the production of next-generation antibodies generate great interest for many biotech and pharmaceutical companies, increase specificity for established cell types, and low intrinsic toxicity. Sacituzumab govitecan, an antibody-drug conjugate (ADC) composed of a humanized anti-Trop-2 antibody conjugated to SN38 is studied for the treatment of patients with metastatic triple-negative breast cancer. Immunomedics, a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer is planning clinical studies of the ADC in other cancers. Market Highlights Global next-generation antibody therapeutics market to surpass USD 14.26 million by 2030 from USD 4.69 million in 2019 at a CAGR of 13.69% throughout the forecast period, i.e. 2019-30. The worldwide increase in the occurrence of different chronic diseases, the increase in the use of therapeutic antibodies, the production and invention of new medicines, and the increase in research and development activities for the preparation of new therapies are the key factors that are fueling the worldwide rise in the demand for next-generation antibody therapeutics.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Global Next-Generation Antibody Therapeutics Market: Segments Oncology Segment to grow with the highest CAGR of XX.X% during 2019-30 Global Next-Generation Antibody Therapeutics Market is segmented by therapeutic area into oncology and autoimmune/inflammatory. The greater market share in 2019 was accounted for by the oncology segment and is expected to see the highest growth during the forecast period due to the rising incidence of cancer globally. The key factors for market growth are the growing prevalence of cancer worldwide, where next-generation antibodies serve as the predominant therapy and new product launches. Antibody-Drug Conjugates segment to grow with the highest CAGR of XX.X% during 2019-30 Global Next-Generation Antibody Therapeutics Market is segmented by technology into Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins, Biosimilar Antibody Products. The greater market share in 2019 was accounted for by ADCs and is estimated to dominate during the forecast period. One of the major developments in the next-generation antibody therapeutics market is the progress in ADC technology. The ADC technology combines the cytotoxic potential of chemotherapy and advantageous characteristics of antibodies, which leads to high specificity and efficiency of ADCs. Global Next-Generation Antibody Therapeutics Market: Market Dynamics Drivers Increasing investments in healthcare infrastructural development During the forecast period, the global next-generation demand for antibody therapeutics is likely to expand at a significant rate. This is largely due to the success of antibody therapeutics for chronic conditions such as cancer and autoimmune diseases of the next generation. Generally speaking, antibody therapeutics have experienced clear scientific developments to improve their effectiveness. Also, due to technological developments in antibody therapeutics and increasing the prevalence of chronic diseases, the market is experiencing substantial growth. Moreover, the growth of the next-generation antibody therapeutics market is driven by increasing healthcare expenditure and growing R&D activities.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Arun Kalwani

Arun Kalwani

Research Analyst

Increasing volume of chronic patients A significant factor in boosting the market for next-generation antibody therapeutics would also be the rising prevalence of chronic disorders. Also, the introduction of technology to support R&D activities is another key factor anticipated to drive the growth of the industry over the next few years. In the antibody therapeutics market, many governments are growing funding and grants for research activities. This, combined with rising spending on healthcare by both developed and developing countries, would also drive demand growth during the forecast period. Restraints High cost involved in research and development for developing next-generation antibodies Different governments have implemented numerous stringent rules and regulations relating to the use of antibodies, which are significantly hampering the global demand for next-generation antibody therapeutics. Also, the high investment required for R&D activities and the preference among medical and healthcare professionals as well as patients for older-generation drug therapies are some of the major issues facing the global market during the forecast period. Global Next-Generation Antibody Therapeutics Market: Regions Global next-generation antibody therapeutics market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA. Global next-generation antibody therapeutics market in North America held the largest market share of XX.X% in the year 2019 and due to growing R&D activities, technical advancements in antibody therapies, growing healthcare expenditure, and increasing government initiatives in this area, growth over the forecast period is expected to be sustained. Also, the growth of the market is driven by the growing prevalence of chronic diseases and by the growing approval of new medicines. It is anticipated that the growing occurrence of multiple diseases, growing advances in therapeutic antibodies, evolving antibody technologies, rising demand for better healthcare services, and rapid growth in biosimilar antibodies and engineered antibodies will bring new opportunities for the region's next-generation therapeutic antibody industry.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Arun Kalwani

Global next-generation antibody therapeutics market is further segmented by region into: North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC Row Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA Global Next-Generation Antibody Therapeutics Market: Recent Development In June 2019, Xencor has initiated the first dose in patients in phase I clinical trial for XmAb22841, a bispecific antibody that targets CTLA-4 and LAG-3 receptor inhibitors for the treatment of advanced solid tumors. If successful, it will change the treatment landscape of patients suffering from advanced solid tumors throughout the world In December 2018, Seattle Genetics, Inc in collaboration with Takeda Pharmaceutical Company Limited has reported in the press release that the ECHELON-2 phase III clinical trial demonstrated clinically meaningful outcomes of brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, and prednisone) for the treatment of CD30-Expressing Peripheral T-cell lymphomas. If SUCCESSFUL, it will bring a potential new treatment option to patients suffering from peripheral T-cell lymphomas across the globe. Global Next-Generation Antibody Therapeutics Market: Key Players Bristol-Myers Squibb Company Overview Business Strategy Key Product Offerings Financial Performance Key Performance Indicators Risk Analysis Recent Development Regional Presence SWOT Analysis Pfizer Roche Bristol-Myers Squibb Amgen AstraZeneca Bayer Takeda Pharmaceuticals Biogen Seattle Genetics ImmunoGen Kyowa Hakko Kirin Xencor Dyax Corp Global Next-Generation Antibody Therapeutics Market report also contains analysis on: Global next-generation antibody therapeutics market Segments: By Therapeutic Area: Oncology Autoimmune/Inflammatory By Technology: Antibody-Drug Conjugates (ADCs) Bispecific Antibodies Fc-engineered Antibodies Antibody Fragments and Antibody-like Proteins Biosimilar Antibody Products Next-generation antibody therapeutics Market Dynamics Next-generation antibody therapeutics Market Size Supply & Demand Current Trends/Issues/Challenges Competition & Companies Involved in the Market Value Chain of the Market Market Drivers and Restraints

Table of Contents

  • Contents
  • 1. Executive Summary
  • 2. Global Liquid Saturated Polyester Resin Market
  • 2.1. Product Overview
  • 2.2. Market Definition
  • 2.3. Segmentation
  • 2.4. Assumptions and Acronyms
  • 3. Research Methodology
  • 3.1. Research Objectives
  • 3.2. Primary Research
  • 3.3. Secondary Research
  • 3.4. Forecast Model
  • 3.5. Market Size Estimation
  • 4. Average Pricing Analysis
  • 5. Macro-Economic Indicators
  • 6. Market Dynamics
  • 6.1. Growth Drivers
  • 6.2. Restraints
  • 6.3. Opportunity
  • 6.4. Trends
  • 7. Correlation & Regression Analysis
  • 7.1. Correlation Matrix
  • 7.2. Regression Matrix
  • 8. Recent Development, Policies & Regulatory Landscape
  • 9. Risk Analysis
  • 9.1. Demand Risk Analysis
  • 9.2. Supply Risk Analysis
  • 10. Global Liquid Saturated Polyester Resin Market Analysis
  • 10.1. Porters Five Forces
  • 10.1.1. Threat of New Entrants
  • 10.1.2. Bargaining Power of Suppliers
  • 10.1.3. Threat of Substitutes
  • 10.1.4. Rivalry
  • 10.2. PEST Analysis
  • 10.2.1. Political
  • 10.2.2. Economic
  • 10.2.3. Social
  • 10.2.4. Technological
  • 11. Global Liquid Saturated Polyester Resin Market
  • 11.1. Market Size & forecast, 2020A-2030F
  • 11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12. Global Liquid Saturated Polyester Resin Market: Market Segmentation
  • 12.1. By Regions
  • 12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.1.5. the Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.2. By Application: Market Share (2020-2030F)
  • 12.2.1. Can & Coil Coatings, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.2.2. Automotive Coatings, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.2.3. 2K PU Coatings, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.2.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.2.5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.3. By End-User: Market Share (2020-2030F)
  • 12.3.1. Food & Beverages, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.3.2. Industrial, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.3.3. Construction, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.3.4. Automotive, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 12.3.5. Other, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  • 13. Company Profile
  • 14. Unitika Ltd
  • 14.1. Company Overview
  • 14.2. Company Total Revenue (Financials)
  • 14.3. Market Potential
  • 14.4. Global Presence
  • 14.5. Key Performance Indicators
  • 14.6. SWOT Analysis
  • 14.7. Product Launch
  • 15. SK Chemicals Co., Ltd.
  • 16. Royal DSM N.V.
  • 17. TOYOBO CO. LTD.
  • 18. Evonik Industries
  • 19. Stepan Company
  • 20. Arkema S.A.
  • 21. Covestro AG
  • 22. Thai Urethane Plastic Co., Ltd.
  • 23. Nippon Gohsei
  • 24. Other Prominent Players
  • Consultant Recommendation
  • **The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Why Bonafide Research?

  • Our seasoned industry experts bring diverse sector experience, tailoring methodologies to your unique challenges.
  • Leveraging advanced technology and time-tested methods ensures accurate and forward-thinking insights.
  • Operating globally with a local touch, our research spans borders for a comprehensive view of international markets.
  • Timely and actionable insights empower swift, informed decision-making in dynamic market landscapes.
  • We foster strong client relationships based on trust, transparency, and collaboration.
  • Our dedicated team adapts and evolves strategies to meet your evolving needs.
  • Upholding the highest standards of ethics and data security, we ensure confidentiality and integrity throughout the research process.

How client has rates us?

Requirement Gathering & Methodology
92%
Data Collection Techniques
97%
Our Research Team & Data Sourcing
93%
Data Science & Analytical Tools
81%
Data Visualization & Presentation Skills
86%
Project/ Report Delivery & After Sales Services
88%
Logo

Global Next-Generation Antibody Therapeutics Market

We are friendly and approachable, give us a call.